# A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

> **NCT05940441** · — · RECRUITING · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 74 (estimated)

## Conditions studied

- to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma

## Interventions

- **DRUG:** Capecitabine 500Mg Oral Tablet

## Key facts

- **NCT ID:** NCT05940441
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940441, "A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05940441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*